UPDATED RESULTS OF A PHASE II STUDY OF LENALIDOMIDE AND RITUXIMAB IN RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA.

被引：0

作者：

Piris-Villaespesa, M. ^{[1
]}

Chavez, J. ^{[2
]}

Dalia, S. ^{[2
]}

Veliz, M. ^{[3
]}

Lancet, Jeffrey ^{[2
]}

Bello, C. ^{[2
]}

Turba, E. ^{[2
]}

Shah, B. ^{[2
]}

Komrokji, R. ^{[2
]}

Sokol, L. ^{[2
]}

Locke, F. ^{[4
]}

Kharfan-Dabaja, M. ^{[4
]}

Sotomayor, E. ^{[2
]}

Pinilla-Ibarz, J. ^{[2
]}

机构：

[1] Hosp Univ Puerta de Hierro Majadahonda, Hematol, Madrid, Spain

[2] H Lee Moffitt Canc Ctr & Res Inst, Malignant Hematol, Tampa, FL USA

[3] Cent Florida Hematol Onc, Hematol, Tampa, FL USA

[4] H Lee Moffitt Canc Ctr & Res Inst, Bone Marrow Transplant, Tampa, FL USA

来源：

HAEMATOLOGICA | 2013年 / 98卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P108

引用

页码：46 / 46

页数：1

共 50 条

[21] Ofatumumab Added To Dexamethasone In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia. Results Fro a Phase II Study Of The Czech Leukemia Study Group For Life
Doubek, Michael
Brychtova, Yvona
Panovska, Anna
Trizuljak, Jakub
Sebejova, Ludmila
Stehlikova, Olga
Chovancova, Jana
Malcikova, Jitka
Smardova, Jana
Plevova, Karla
Volfova, Pavlina
Trbusek, Martin
Mraz, Marek
Majercakova, Denisa
Obrtlikova, Petra
Karban, Josef
Smolej, Lukas
Lindtnerova, Michaela
Oltova, Alexandra
Jelinkova, Eva
Pospisilova, Sarka
Mayer, Jiri
BLOOD, 2013, 122 (21)
[22] Updated Results from the Phase II Study of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia
Xu, Wei
Song, Yongping
Wang, Tingyu
Yang, Shenmiao
Liu, Lihong
Hu, Yu
Zhang, Wei
Zhou, Jianfeng
Gao, Sujun
Ding, Kaiyang
Zhang, Huilai
Zhu, Zunmin
Wang, Shun-Qing
Xu, Bing
Hu, Jianda
Liu, Ting
Ji, Chunyan
Xia, Zhongjun
Li, Yan
Wang, Xin
Zhu, Huaqiang
Zhao, Renbin
Zhang, Bin
Xu, Zhixin
Li, Jianyong
BLOOD, 2020, 136
[23] Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results
Byrd, John C.
Wierda, William G.
Schuh, Anna
Devereux, Stephen
Chaves, Jorge M.
Brown, Jennifer R.
Hillmen, Peter
Martin, Peter
Awan, Farrukh T.
Stephens, Deborah M.
Ghia, Paolo
Barrientos, Jacqueline
Pagel, John M.
Woyach, Jennifer A.
Burke, Kathleen
Covey, Todd
Gulrajani, Michael
Hamdy, Ahmed
Izumi, Raquel
Frigault, Melanie M.
Patel, Priti
Rothbaum, Wayne
Wang, Min Hui
O'Brien, Susan
Furman, Richard R.
BLOOD, 2020, 135 (15) : 1204 - 1213
[24] Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
Fischer, Kirsten
Cramer, Paula
Busch, Raymonde
Stilgenbauer, Stephan
Bahlo, Jasmin
Schweighofer, Carmen D.
Boettcher, Sebastian
Staib, Peter
Kiehl, Michael
Eckart, Michael J.
Kranz, Gabriele
Goede, Valentin
Elter, Thomas
Buehler, Andreas
Winkler, Dirk
Kneba, Michael
Doehner, Hartmut
Eichhorst, Barbara F.
Hallek, Michael
Wendtner, Clemens-Martin
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (26) : 3559 - 3566
[25] Economic burden of relapsed/refractory chronic lymphocytic leukemia.
Guerin, Annie
Ray, Saurabh
Gauthier, Genevieve
Hsu, Ling-I
Zhdanava, Maryia
Heroux, Julie
Wu, Eric Qiong
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[26] Acalabrutinib Versus Idelalisib Plus Rituximab (IdR) or Bendamustine Plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final Results
Ghia, Paolo
Pluta, Andrzej
Wach, Malgorzata
Lysak, Daniel
Kozak, Tomas
Simkovic, Martin
Kaplan, Polina
Kraychok, Iryna
Illes, Arpad
de la Serna, Javier
Dolan, Sean
Campbell, Philip
Musuraca, Gerardo
Jacob, Abraham
Avery, Eric J.
Lee, Jae Hoon
Wang, Denise
Patel, Priti
Jurczak, Wojciech
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S220 - S221
[27] ACALABRUTINIB VS IDELALISIB PLUS RITUXIMAB (IDR) OR BENDAMUSTINE PLUS RITUXIMAB (BR) IN RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF ASCEND
Ghia, Paolo
Pluta, Andrzej
Wach, Malgorzata
Lysak, Daniel
Kozak, Tomas
Simkovic, Martin
Kaplan, Polina
Kraychok, Iryna
Illes, Arpad
De la Serna, Javier
Dolan, Sean
Campbell, Philip
Musuraca, Gerardo
Jacob, Abraham
Avery, Eric J.
Lee, Jae Hoon
Wang, Denise
Patel, Priti
Jurcza, Wojciech
HAEMATOLOGICA, 2020, 105 : 205 - 206
[28] Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
Fraser, G.
Cramer, P.
Demirkan, F.
Silva, R. Santucci
Grosicki, S.
Pristupa, A.
Janssens, A.
Mayer, J.
Bartlett, N. L.
Dilhuydy, M-S
Pylypenko, H.
Loscertales, J.
Avigdor, A.
Rule, S.
Villa, D.
Samoilova, O.
Panagiotidis, P.
Goy, A.
Pavlovsky, M. A.
Karlsson, C.
Hallek, M.
Mahler, M.
Salman, M.
Sun, S.
Phelps, C.
Balasubramanian, S.
Howes, A.
Chanan-Khan, A.
LEUKEMIA, 2019, 33 (04) : 969 - 980
[29] Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
G. Fraser
P. Cramer
F. Demirkan
R. Santucci Silva
S. Grosicki
A. Pristupa
A. Janssens
J. Mayer
N. L. Bartlett
M.-S. Dilhuydy
H. Pylypenko
J. Loscertales
A. Avigdor
S. Rule
D. Villa
O. Samoilova
P. Panagiotidis
A. Goy
M. A. Pavlovsky
C. Karlsson
M. Hallek
M. Mahler
M. Salman
S. Sun
C. Phelps
S. Balasubramanian
A. Howes
A. Chanan-Khan
Leukemia, 2019, 33 : 969 - 980
[30] Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study)
Wendtner, Clemens
Hillmen, Peter
Mahadevan, Daruka
Stilgenbauer, Stephan
Uharek, Lutz
Coutre, Steven
Frankfurt, Olga
Bloor, Adrian
Bosch, Francesc
Furman, Richard R.
Kimby, Eva
Gribben, John G.
Gobbi, Marco
Dreisbach, Luke
Hurd, David Duane
Sekeres, Mikkael A.
Ferrajoli, Alessandra
Shah, Sheetal
Zhang, Jennie
de Parseval, Laure Moutouh
Chanan-Khan, Asher A.
BLOOD, 2010, 116 (21) : 591 - 592

← 1 2 3 4 5 →